$4.54
0[0.00%]
At close: Apr 23
$4.54
0[0.00%]
PreMarket: 4:05PM EDT
Fate Therapeutics
(NASDAQ:FATE)Fate Therapeutics Stock (NASDAQ:FATE), Analyst Ratings, Price Targets, Predictions
Fate Therapeutics Inc has a consensus price target of $9.43, established from looking at the 64 latest analyst ratings. The last 3 analyst ratings were released from Wedbush, Needham, and B of A Securities on April 23, 2024, April 11, 2024, and March 28, 2024. With an average price target of $4.33 between Wedbush, Needham, and B of A Securities, there's an implied -4.55% downside for Fate Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
Needham
B of A Securities
HC Wainwright & Co.
Morgan Stanley
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Fate Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/23/2024 | FATE | Buy Now | Fate Therapeutics | $4.54 | 54.19% | Wedbush | David Nierengarten | → $7 | Reiterates | Neutral → Neutral | Get Alert |
| 04/11/2024 | FATE | Buy Now | Fate Therapeutics | $4.54 | — | Needham | Gil Blum | — | Reiterates | → Hold | Get Alert |
| 03/28/2024 | FATE | Buy Now | Fate Therapeutics | $4.54 | 32.16% | B of A Securities | Tazeen Ahmad | $2 → $6 | Maintains | Underperform | Get Alert |
| 03/19/2024 | FATE | Buy Now | Fate Therapeutics | $4.54 | 54.19% | HC Wainwright & Co. | Raghuram Selvaraju | → $7 | Reiterates | → Neutral | Get Alert |
| 02/27/2024 | FATE | Buy Now | Fate Therapeutics | $4.54 | 54.19% | Morgan Stanley | Michael Ulz | $3 → $7 | Maintains | Equal-Weight | Get Alert |
| 02/27/2024 | FATE | Buy Now | Fate Therapeutics | $4.54 | 54.19% | BMO Capital | Etzer Darout | $6 → $7 | Maintains | Market Perform | Get Alert |
| 02/27/2024 | FATE | Buy Now | Fate Therapeutics | $4.54 | 120.26% | Barclays | Peter Lawson | $6 → $10 | Maintains | Overweight | Get Alert |
| 02/27/2024 | FATE | Buy Now | Fate Therapeutics | $4.54 | 54.19% | Wedbush | David Nierengarten | $3 → $7 | Maintains | Neutral | Get Alert |
| 02/27/2024 | FATE | Buy Now | Fate Therapeutics | $4.54 | — | Oppenheimer | Matthew Biegler | — | Reiterates | Perform → Perform | Get Alert |
| 11/20/2023 | FATE | Buy Now | Fate Therapeutics | $4.54 | 76.21% | Mizuho | Mara Goldstein | $12 → $8 | Maintains | Buy | Get Alert |
| 11/13/2023 | FATE | Buy Now | Fate Therapeutics | $4.54 | -33.92% | Morgan Stanley | Michael Ulz | $5 → $3 | Maintains | Equal-Weight | Get Alert |
| 11/09/2023 | FATE | Buy Now | Fate Therapeutics | $4.54 | 32.16% | BMO Capital | Etzer Darout | $5.4 → $6 | Maintains | Market Perform | Get Alert |
| 11/09/2023 | FATE | Buy Now | Fate Therapeutics | $4.54 | -33.92% | Wedbush | David Nierengarten | $6 → $3 | Maintains | Neutral | Get Alert |
| 11/09/2023 | FATE | Buy Now | Fate Therapeutics | $4.54 | 10.13% | Wells Fargo | Yanan Zhu | $6 → $5 | Maintains | Equal-Weight | Get Alert |
| 09/07/2023 | FATE | Buy Now | Fate Therapeutics | $4.54 | 10.13% | Cantor Fitzgerald | Li Watsek | → $5 | Reiterates | Neutral → Neutral | Get Alert |
| 08/16/2023 | FATE | Buy Now | Fate Therapeutics | $4.54 | 54.19% | Truist Securities | Robyn Karnauskas | → $7 | Reiterates | Hold → Hold | Get Alert |
| 08/10/2023 | FATE | Buy Now | Fate Therapeutics | $4.54 | 10.13% | Morgan Stanley | Michael Ulz | $8 → $5 | Maintains | Equal-Weight | Get Alert |
| 08/10/2023 | FATE | Buy Now | Fate Therapeutics | $4.54 | 32.16% | Barclays | Peter Lawson | $12 → $6 | Maintains | Overweight | Get Alert |
| 08/09/2023 | FATE | Buy Now | Fate Therapeutics | $4.54 | 18.94% | BMO Capital | Etzer Darout | $6 → $5.4 | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Fate Therapeutics (FATE)?
The latest price target for Fate Therapeutics (NASDAQ: FATE) was reported by Wedbush on April 23, 2024. The analyst firm set a price target for $7.00 expecting FATE to rise to within 12 months (a possible 54.19% upside). 23 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Fate Therapeutics (FATE)?
The latest analyst rating for Fate Therapeutics (NASDAQ: FATE) was provided by Wedbush, and Fate Therapeutics reiterated their neutral rating.
When was the last upgrade for Fate Therapeutics (FATE)?
The last upgrade for Fate Therapeutics Inc happened on July 12, 2022 when BMO Capital raised their price target to $47. BMO Capital previously had a market perform for Fate Therapeutics Inc.
When was the last downgrade for Fate Therapeutics (FATE)?
The last downgrade for Fate Therapeutics Inc happened on January 24, 2023 when HC Wainwright & Co. changed their price target from $115 to $7 for Fate Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Fate Therapeutics (FATE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fate Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fate Therapeutics was filed on April 23, 2024 so you should expect the next rating to be made available sometime around April 23, 2025.
Is the Analyst Rating Fate Therapeutics (FATE) correct?
While ratings are subjective and will change, the latest Fate Therapeutics (FATE) rating was a reiterated with a price target of $0.00 to $7.00. The current price Fate Therapeutics (FATE) is trading at is $4.54, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.